Plexus Corporation
PLXS
$0.00
-5.19%
Plexus Corp is a global electronics manufacturing services (EMS) provider that designs, manufactures, and services complex products for regulated industries, including life-saving medical devices, mission-critical aerospace and defense systems, industrial automation, and semiconductor capital equipment. The company differentiates itself through its integrated lifecycle solutions—spanning design, supply chain, manufacturing, and sustaining services—and operates across three segments: AMER, APAC, and EMEA, with the majority of revenue generated in APAC. Currently, the investor narrative centers on Plexus's strong growth trajectory, driven by robust demand in healthcare and aerospace/defense, as well as its expanding margins and improving profitability. The stock has also attracted attention for its significant price appreciation over the past year, reflecting confidence in its strategic positioning and operational execution.…
PLXS
Plexus Corporation
$0.00
Investment Opinion: Should I buy PLXS Today?
Rating: Buy. Plexus offers an attractive risk/reward with accelerating revenue growth, improving margins, and a low PEG ratio of 0.40, supported by a strong balance sheet. The limited analyst coverage (2 analysts) suggests the stock may be underfollowed, providing an opportunity for discovery.
Supporting Evidence: Revenue grew 9.6% YoY in Q1 FY2026, accelerating from prior quarters. The trailing P/E of 22.4x is reasonable given the estimated EPS growth to $10.36 (forward P/E 29.0x). The PEG ratio of 0.40 indicates undervaluation relative to growth. Operating margin improved to 5.09% from 4.80% a year ago, and the company has a low debt-to-equity ratio of 0.12. The price-to-sales ratio of 0.96x is below the industry average of ~1.5x, suggesting value.
Risks & Conditions: The biggest risks are margin compression from cost inflation and negative free cash flow. If revenue growth decelerates below 5% or gross margins fall below 9%, the rating would be downgraded to Hold. Conversely, if free cash flow turns positive and margins expand above 11%, it would strengthen the Buy case. Overall, the stock appears fairly valued relative to its history but undervalued on a PEG basis, making it a Buy for growth-oriented investors.
Sign up to view all
PLXS 12-Month Price Forecast
Plexus is well-positioned for continued growth driven by secular demand in healthcare and aerospace/defense. The accelerating revenue trend and improving margins support a bullish stance, while the low PEG ratio suggests the stock is undervalued relative to its growth potential. However, the recent 97.8% rally and thin margins warrant caution. The base case of stable growth and valuation is most likely, but if the company delivers on margin expansion and free cash flow improvement, the bull case could materialize. A downgrade to neutral would occur if revenue growth decelerates below 5% or gross margins fall below 9%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Plexus Corporation's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
2 analysts
Implied Upside
—
vs. current price
Analyst Count
2
covering this stock
Price Range
$0 - $0
Analyst target range
Only 2 analysts cover Plexus, which is limited coverage for a mid-cap stock. The consensus recommendation is not explicitly provided, but the institutional ratings show a mix of Buy and Hold ratings from firms like Benchmark, Needham, and Stifel. The average estimated EPS is $10.36, with a range of $10.24 to $10.48, and average estimated revenue is $5.626 billion. Without explicit price targets, we cannot calculate upside/downside. However, the limited coverage implies that Plexus may be underfollowed, which can lead to higher volatility and less efficient price discovery. The narrow EPS range suggests analysts have relatively high conviction on near-term earnings. The lack of a consensus target price is a gap, but the positive ratings from multiple firms indicate a generally bullish sentiment. Investors should monitor for additional analyst initiation or upgrades as the company continues to grow.
Bulls vs Bears: PLXS Investment Factors
Plexus presents a compelling growth story with accelerating revenue, improving margins, and a strong balance sheet, supported by a low PEG ratio of 0.40 that suggests undervaluation relative to growth. However, the stock trades near its 52-week high after a nearly 100% rally, and thin margins typical of the EMS industry leave it vulnerable to cost pressures. The bull case is currently stronger due to the accelerating growth trajectory and attractive valuation, but the key tension is whether the company can sustain its growth momentum and expand margins to justify the current price. If revenue growth continues to accelerate and margins improve, the stock could re-rate higher; if growth decelerates or margins compress, the stock could correct significantly.
Bullish
- Accelerating Revenue Growth: Revenue grew 9.6% YoY in Q1 FY2026 to $1.070B, accelerating from 0.6% in Q4 FY2025 and 5.4% in Q3 FY2025, driven by strong demand in healthcare and aerospace/defense.
- Low Valuation vs. Growth: PEG ratio of 0.40 suggests the stock is undervalued relative to its earnings growth rate, with a forward P/E of 29.0x and estimated EPS growth to $10.36.
- Strong Balance Sheet: Debt-to-equity ratio of 0.12 and current ratio of 1.58 indicate low leverage and adequate liquidity, reducing financial risk.
- Improving Profitability: Operating margin improved to 5.09% in Q1 FY2026 from 4.80% a year ago, and net margin rose to 3.85% from 3.82%, reflecting better cost control.
Bearish
- Thin Margins in EMS Industry: Gross margin of 9.92% and net margin of 3.85% are typical for the EMS industry but leave little room for error; any cost inflation or pricing pressure could compress margins further.
- Negative Free Cash Flow: Free cash flow was -$50.6M in Q1 FY2026 due to working capital investments, raising concerns about cash generation despite trailing twelve-month FCF of $76.3M.
- Limited Analyst Coverage: Only 2 analysts cover PLXS, which may lead to less efficient price discovery and higher volatility; lack of consensus price targets reduces visibility.
- Near 52-Week High: At $275.11, the stock is at 89.6% of its 52-week high of $307.06, suggesting limited upside potential and risk of a pullback after a 97.8% gain over the past year.
PLXS Technical Analysis
Plexus is in a sustained uptrend, with the stock price up 97.8% over the past year, dramatically outperforming the S&P 500's 19.1% gain. The current price of $275.11 sits at 89.6% of its 52-week range ($115.35 to $307.06), indicating the stock is trading near the upper end of its range, which suggests strong momentum but also potential overextension. The 52-week low of $115.35 and high of $307.06 provide clear boundaries for the trend. Short-term momentum shows a 1-month price change of -1.79%, a deceleration from the 3-month change of +32.68% and the 6-month change of +80.72%. This divergence—where the 1-year trend is strongly bullish but the 1-month trend is slightly negative—could signal a temporary pullback or consolidation within the broader uptrend. The relative strength index (RSI) is not directly provided, but the price action suggests the stock may be cooling off after a rapid ascent. Key technical support is at the 52-week low of $115.35, while resistance is at the 52-week high of $307.06. A breakout above $307.06 would signal a continuation of the uptrend, while a breakdown below $115.35 would indicate a trend reversal. The stock's beta of 0.879 indicates it is less volatile than the overall market, meaning it may offer a smoother ride during market swings, but its recent price action has been more volatile than its beta suggests.
Beta
0.88
0.88x market volatility
Max Drawdown
-15.5%
Largest decline past year
52-Week Range
$115-$307
Price range past year
Annual Return
+97.8%
Cumulative gain past year
| Period | PLXS Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +1.0% |
| 3m | +32.7% | +13.0% |
| 6m | +80.7% | +7.7% |
| 1y | +97.8% | +19.1% |
| ytd | +80.7% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PLXS Fundamental Analysis
Plexus's revenue trajectory is accelerating, with the most recent quarter (Q1 FY2026, ended January 3, 2026) reporting revenue of $1.070 billion, up 9.6% year-over-year from $976 million in the prior-year quarter. This marks a clear acceleration from the 0.6% YoY growth seen in Q4 FY2025 and the 5.4% growth in Q3 FY2025. The Asia Pacific segment contributed the largest share at $611.7 million (57% of total), followed by the Americas at $344.8 million (32%) and EMEA at $118.4 million (11%). The growth is driven by strong demand in healthcare/life sciences and aerospace/defense, which are core to Plexus's strategy. The company is profitable, with net income of $41.2 million in the most recent quarter, up from $37.3 million a year ago. Gross margin has been stable around 9.9% to 10.3% over the past year, with the latest quarter at 9.92%, slightly below the 10.32% in Q1 FY2025. Operating margin improved to 5.09% from 4.80% a year ago, reflecting better cost control. Net margin was 3.85%, up from 3.82% in the prior-year quarter. While margins remain thin, typical for the EMS industry, the trend is positive. Plexus has a strong balance sheet with a debt-to-equity ratio of 0.12, indicating low leverage. The current ratio of 1.58 suggests adequate liquidity. Free cash flow (FCF) was negative $50.6 million in the most recent quarter due to working capital investments, but trailing twelve-month FCF was $76.3 million, implying a FCF yield of about 2.0% based on the current market cap. Return on equity (ROE) was 11.9%, reflecting solid profitability relative to equity.
Quarterly Revenue
$1.1B
2026-01
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.09%
Latest Quarter
Free Cash Flow
$76282000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PLXS Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 22.4x, while the forward P/E is 29.0x, based on estimated EPS of $10.36. The gap between trailing and forward P/E suggests the market expects earnings growth, as the forward multiple is higher. The PEG ratio of 0.40 indicates the stock is undervalued relative to its growth rate, assuming the growth estimates are accurate. Compared to the industry average (not provided directly, but the sector median P/E for Technology Hardware & Equipment is around 20x), Plexus's trailing P/E of 22.4x represents a slight premium. However, given its strong growth and market position, this premium may be justified. Historically, Plexus's trailing P/E has ranged from about 12x to 40x over the past five years. The current 22.4x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The price-to-sales ratio of 0.96x is low, reflecting the thin-margin nature of the EMS business, and is below the industry average of around 1.5x, which could indicate a value opportunity if margins expand.
PE
22.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Plexus's thin gross margin of 9.92% and net margin of 3.85% leave it vulnerable to cost inflation or pricing pressure from customers. The negative free cash flow of -$50.6M in Q1 FY2026, driven by working capital investments, could strain liquidity if sustained. However, the low debt-to-equity ratio of 0.12 and current ratio of 1.58 provide a buffer. Revenue concentration in APAC (57% of total) exposes the company to geopolitical and supply chain risks in the region.
Market & Competitive Risks: The stock's beta of 0.879 indicates lower market correlation, but its 97.8% gain over the past year may have priced in optimistic expectations. Limited analyst coverage (only 2 analysts) can lead to sudden price swings on earnings surprises. The EMS industry is highly competitive with low switching costs, and larger players like Foxconn could pressure margins. No recent news highlights specific threats, but macro headwinds such as a recession could reduce demand from healthcare and aerospace customers.
Worst-Case Scenario: A severe economic downturn could cause customers to delay orders, leading to revenue contraction and margin compression. If the stock reverts to its 52-week low of $115.35, an investor would face a loss of approximately -58% from the current price of $275.11. This scenario could be triggered by a sharp decline in healthcare or defense spending, or a major customer loss.
FAQ
The key risks include: 1) Margin risk: Gross margins of 9.92% are thin and could be compressed by cost inflation or pricing pressure. 2) Growth sustainability: Revenue growth of 9.6% YoY may decelerate if healthcare or defense demand softens. 3) Negative free cash flow: -$50.6M in Q1 FY2026 could persist if working capital needs remain high. 4) Limited analyst coverage: Only 2 analysts cover the stock, which can lead to higher volatility and less efficient price discovery. The most severe risk is a recession that reduces demand, potentially sending the stock back to its 52-week low of $115.35.
The 12-month forecast is cautiously bullish. In the base case (45% probability), the stock trades in a range of $275-$307, with stable growth and margins. In the bull case (30% probability), the stock could reach $307-$340 if growth accelerates and margins expand. In the bear case (25% probability), the stock could fall to $200-$250 if growth decelerates or margins compress. The most likely scenario is the base case, where the stock maintains its current valuation as the market digests the recent rally. Key assumptions include sustained demand in healthcare and defense, and stable gross margins around 10%.
PLXS appears fairly valued to slightly undervalued based on its PEG ratio of 0.40, which indicates the stock is cheap relative to its earnings growth rate. The trailing P/E of 22.4x is in the middle of its historical range of 12x-40x, suggesting it is not overvalued compared to its own history. The price-to-sales ratio of 0.96x is below the industry average of around 1.5x, which could indicate a value opportunity if margins expand. However, the forward P/E of 29.0x is elevated, reflecting market expectations for continued growth. Overall, the valuation is reasonable given the growth trajectory.
PLXS appears to be a good buy for growth-oriented investors given its accelerating revenue growth (9.6% YoY), low PEG ratio of 0.40, and strong balance sheet. The stock has a trailing P/E of 22.4x, which is reasonable for its growth rate, and analysts estimate EPS of $10.36 for the current fiscal year. However, the stock is near its 52-week high after a 97.8% rally, so there is limited short-term upside and risk of a pullback. The biggest downside risk is margin compression in the thin-margin EMS industry. For long-term investors, the risk/reward is favorable, but short-term traders should be cautious.
PLXS is more suitable for long-term investment given its growth profile and low beta of 0.879, which offers downside protection. The company's focus on regulated industries provides secular growth tailwinds, and the low PEG ratio suggests long-term value. Short-term traders may find limited upside near the 52-week high and could face volatility from limited analyst coverage. A minimum holding period of 12-18 months is recommended to allow the growth story to play out and for free cash flow to improve. The stock does not pay a dividend, so it is not suitable for income investors.